Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaust Limited ( (AU:NUZ) ) has issued an announcement.
Neurizon Therapeutics has requested and been granted a trading halt on its ordinary shares and listed options on the ASX, effective from 19 December 2025, as it prepares to announce the outcome of a proposed capital raising. The halt, which is intended to help the company manage its continuous disclosure obligations, will remain in place until either the announcement is released or normal trading resumes on 23 December 2025, signaling that a potentially significant funding development is imminent for investors and other stakeholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is an Australia-based biotechnology company listed on the ASX, focused on developing therapeutic treatments in the healthcare sector. Its securities, including ordinary shares and listed options, trade under the tickers NUZ and NUZOA on the Australian Securities Exchange.
Average Trading Volume: 817,047
Technical Sentiment Signal: Sell
Current Market Cap: A$58.82M
Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.